Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2024-12-23 Board/Management Inform…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax Announces a Change to the Composition of its Board of Directors
Board/Management Information Classification · 1% confidence The document is titled "Abivax Announces a Change to the Composition of its Board of Directors" and details the resignation of a director (Dr. Philippe Pouletty) and the subsequent plans for board composition. This content directly relates to changes in the company's governing body. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is a formal announcement (EQS-News) but it is the substance of the change itself, not just an announcement that a report is forthcoming (which would suggest RPA or RNS). Therefore, MANG is the most appropriate classification.
2024-12-23 English
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.11.24.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated December 18, 2024, titled 'Informations relatives au nombre total de droits de vote et d'actions' (Information relating to the total number of shares and voting rights). It explicitly references Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF). This type of mandatory disclosure, detailing the total number of shares and voting rights as of a specific date (30/11/2024), is a standard regulatory filing in France. While it relates to capital structure, it is not a general capital change announcement (SHA) or a transaction in own shares (POS). It is a specific, periodic regulatory disclosure concerning voting rights. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit for official reporting of voting rights counts, even though it is not the result of a vote, but the underlying structure required for shareholder meetings and threshold crossing calculations. Given the highly specific nature of the content (share count and voting rights calculation based on AMF rules), DVA is the best match.
2024-12-18 French
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote au 31.10.24.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated November 27, 2024, titled "Nombre d'actions composant le capital social et nombre total de droits de vote" (Number of shares comprising the share capital and total number of voting rights). It explicitly references French regulatory articles (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation) and provides a table detailing the number of shares and voting rights as of a specific date (31/10/2024). This type of mandatory disclosure regarding the total share capital and voting rights structure is a specific regulatory filing requirement, often related to capital structure changes or required periodic updates. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit as it deals directly with the composition of the share capital and voting rights, which underpins capital structure reporting. It is not a general earnings release (ER), a full annual report (10-K), or a dividend notice (DIV).
2024-11-27 French
Abivax met en place un programme « At-the-Market (ATM) » sur le Nasdaq
Capital/Financing Update Classification · 1% confidence The document is a press release from Abivax announcing the establishment of an 'At-the-Market' (ATM) program to sell up to $150 million in American Depositary Shares (ADSs) over three years. This involves the issuance and sale of new shares/ADSs to raise capital for clinical programs and working capital. This activity directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full 10-K, an earnings release (ER), or a simple dividend notice (DIV). It is an announcement of a financing mechanism, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it details the terms of the capital raise itself.
2024-11-19 French
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Capital/Financing Update Classification · 1% confidence The document is a press release dated November 19, 2024, announcing that Abivax has established an At-the-Market (ATM) program on Nasdaq, allowing the sale of up to $150,000,000 in American Depositary Shares (ADSs). It details the terms, the role of the sales agent (Piper Sandler), the filing of a shelf registration statement on Form F-3 with the SEC, and the intended use of proceeds. This announcement concerns a specific financing activity—the establishment of a mechanism to issue and sell new shares/securities to raise capital. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate financing action.
2024-11-19 English
Abivax présente les principales informations financières du troisième trimestre 2024
Earnings Release Classification · 1% confidence The document explicitly states it presents the "principales informations financières du troisième trimestre 2024" (key financial information for the third quarter of 2024) and includes unaudited consolidated results, cash position, and debt details as of September 30, 2024. This content structure—a summary of financial highlights for a specific interim period (Q3)—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it focuses on key figures and cash flow rather than full income statements and balance sheets, making ER the most appropriate classification. The document length (9031 chars) is substantial enough to be the release itself, not just a brief announcement of a report (RPA/RNS). Q3 2024
2024-11-14 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.